Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Benefits And Health Insurance topic

No spam. Unsubscribe anytime.

Shawnee Mission approves 9.8% medical-insurance renewal; district monthly contribution to rise to $982

Shawnee Mission School District Board of Education · August 26, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Board approved renewal of the district’s medical insurance with Blue Cross Blue Shield of Kansas City, reflecting a 9.8% increase in planning cost and raising the district contribution to $982 per month; CBIZ presented claims and prescription-cost drivers.

The Shawnee Mission School District board authorized renewal of the district’s medical-insurance program with Blue Cross and Blue Shield of Kansas City effective Jan. 1, 2026, approving the rates the district negotiated during earlier bargaining.

CBIZ senior benefits consultant Dave Johnson told the board that claims experience from March 2024 through February 2025 was slightly above expectations and that prescription-drug expenses were a major driver of cost increases. Johnson said prescription costs were up roughly 10–13 percent in some measures and noted the plan saw 27 pooled claims over the insurer’s pooling threshold; the overall renewal result presented to the board was a 9.8% increase.

The renewal the board authorized increases the district’s monthly contribution to $982. Johnson and Associate Superintendent Jeremy Higgins highlighted that the district still offers four employee-only plans at no premium cost for employees and that two high-deductible plan options include district HSA contributions. Higgins said open enrollment for employees will run from Sept. 29 through Oct. 17 and staff will distribute benefits information in the coming days.

Board members asked detailed questions about whether higher costs were caused by market price increases versus changes in utilization, how frequently actuarial estimates diverge from actuals, and whether members could appeal formulary decisions when a drug moves to a biosimilar. Johnson described an appeals process and said exceptions are possible when clinically necessary.

The board moved to authorize the Blue Cross Blue Shield renewal and voted to approve the recommendation (record shows the board approved the authorization 6–0).